Patent ID: 9084781
Filing Date: 2015-07-21
Classification: A61K,A61P,C12N,G01N

Abstract:
1. A method of optimizing treatment of a subject having cancer, comprising: (a) extracting nucleic acid from cells of the cancer; (b) assaying a nucleic acid molecule encoding a MEK polypeptide and identifying the nucleotide sequence of a nucleic acid molecule encoding a MEK polypeptide to identify an alteration of an amino acid residue at one or more amino acids of the encoded MEK polypeptide that confers resistance to a MEK inhibitor and identifying the presence of nucleotides that alter the identity of an amino acid residue at one or more amino acids of the encoded MEK polypeptide relative to the amino acid at one or more positions selected from the group consisting of I103N, I111N, L115R, L115P, H119P, P124L, P124S, F129L and V211D of SEQ ID NO:2, the altered identity of the amino acid residue at one or more amino acids of the encoded MEK polypeptide confers resistance to a MEK inhibitor and indicates a need to treat the subject with a MEK inhibitor and a RAF inhibitor; and (c) administering a MEK inhibitor and a RAF inhibitor to the subiect when the nucleic acid molecule includes nucleotides that alter the identity of an amino acid residue at one or more amino acid of the encoded MEK polypeptide relative to the amino acid at one or more positions selected from the group consisting I103N, I111N, L115R, L115P, H119P, P124L, P124S, F129L and V211D of SEQ ID NO:2, and the altered identity of the amino acid residue at one or more amino acids of the encoded MEK polypeptide confers resistance to a MEK inhibitor.